LZLin Zheng

Lin Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lin Zheng has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Enyu Wang

    Department of Radiology, Taizhou Campus of Zhejiang Cancer Hospital (Taizhou Cancer Hospital), Taizhou, China

    1 shared publication
  • Feng Xuan

    Department of Radiation Oncology, Zhuji Affiliated Hospital of Wenzhou Medical University, Shaoxing, Zhejiang, China

    1 shared publication
  • Hai-Hong Zheng

    Department of Urology, Taizhou Hospital of Zhejiang Province affiliated with Wenzhou Medical University, Linhai, Taizhou, Zhejiang, China

    1 shared publication
  • Jiajia Wang

    TCM Department, Hospital of Taizhou, Taizhou, China

    1 shared publication
  • Li-Cai Mo

    Department of Urology, Taizhou Hospital of Zhejiang Province affiliated with Wenzhou Medical University, Linhai, Taizhou, Zhejiang, China

    1 shared publication
  • Lingying Zhu

    Department of Radiology, Taizhou Campus of Zhejiang Cancer Hospital (Taizhou Cancer Hospital), Taizhou, China

    1 shared publication

Latest Publications

  • Open Access

    Analysis of the correlation between inflammatory cytokines and glioblastoma: A Mendelian randomization study

    by Feng Mb Xuan, Tian Mb Lv, Lin Mm Zheng, Shengjian Mm Yu, Mengjuan Mb Ding

    Epidemiological studies have demonstrated that inflammatory cytokines are associated with cancer development. However, the causal relationship between inflammatory cytokines and glioblastoma remains unclear. We used a two-sample Mendelian randomization approach to determine the potential causal effects of inflammatory cytokines on glioblastoma. Genome-wide association study summary statistics for 41 inflammatory cytokines were obtained from the University of Bristol database, and 91 inflammatory cytokines were acquired from the genome-wide association study catalog database. Genetic data on glioblastoma were downloaded from the FinnGen consortium (R10). Mendelian randomization analysis and Bayesian weighted Mendelian randomization analysis were performed to investigate the causal relationship between inflammatory cytokines and glioblastoma risk. A combination of Mendelian randomization (MR)-Egger, MR-Pleiotropy Residual Sum and Outliers, and Radial MR methods was employed to assess horizontal pleiotropy, which is a potential bias in MR studies. The Cochran Q test was used to quantify the degree of heterogeneity. Finally, we conducted a comprehensive meta-analysis to confirm the robustness of our findings. Increased levels of tumor necrosis factor β (odds ratio [OR] = 1.597, 95% CI: 1.143–2.230, P = .006) and interleukin-10 (OR = 1.452, 95% CI: 1.059–1.992, P = .021) were associated with an increased risk of glioblastoma. Conversely, higher levels of circulating fibroblast growth factor 21 (OR = 0.456, 95% CI: 0.276–0.754, P = .002) and macrophage inflammatory protein 1a (OR = 0.743, 95% CI: 0.558–0.990, P = .042) were associated with a decreased risk of glioblastoma. No significant causal effect on inflammatory cytokines from glioblastoma was detected, and no significant heterogeneity in instrumental variables or horizontal pleiotropy was observed. Our findings indicate that specific inflammatory cytokines may play a role in glioblastoma development, acting as either protective factors or risk factors. This offers valuable insights into the disease mechanism and suggests that targeting these cytokines could be a potential strategy for glioblastoma prevention and treatment.


  • Open Access

    Development of a novel nomogram for predicting clinically significant prostate cancer with the prostate health index and multiparametric MRI

    by Li-Cai Mo, Xian-Jun Zhang, Hai-Hong Zheng, Xiao-Peng Huang, Lin Zheng, Zhi-Rui Zhou, Jia-Jia Wang

    Introduction: On prostate biopsy, multiparametric magnetic resonance imaging (mpMRI) and the Prostate Health Index (PHI) have allowed prediction of clinically significant prostate cancer (csPCa).Methods: To predict the likelihood of csPCa, we created a nomogram based on a multivariate model that included PHI and mpMRI. We assessed 315 males who were scheduled for prostate biopsies.Results: We used the Prostate Imaging Reporting and Data System version 2 (PI-RADS V2) to assess mpMRI and optimize PHI testing prior to biopsy. Univariate analysis showed that csPCa may be identified by PHI with a cut-off value of 77.77, PHID with 2.36, and PI-RADS with 3 as the best threshold. Multivariable logistic models for predicting csPCa were developed using PI-RADS, free PSA (fPSA), PHI, and prostate volume. A multivariate model that included PI-RADS, fPSA, PHI, and prostate volume had the best accuracy (AUC: 0.882). Decision curve analysis (DCA), which was carried out to verify the nomogram’s clinical applicability, showed an ideal advantage (13.35% higher than the model that include PI-RADS only).Discussion: In conclusion, the nomogram based on PHI and mpMRI is a valuable tool for predicting csPCa while avoiding unnecessary biopsy as much as possible.